One meta-analysis involving patients with T2D without cardiovascular disease found a reduction in MACE associated with SGLT2i regimens of (adjusted pooled OR and 95% CI) 0.82 (0.730.92), with GLP1-RAs regimens of 0.93 (0.811.06), and with combined therapy of 0.70 (0.500.98)
Source: Glycyl-l-histidyl-l-lysine prevents copper- and zinc-induced protein aggregation and central nervous system cell death in vitro (2024) RapAdmin April 14, 2026, 4:18pm #3 Part 4: Actionable Intelligence The Translational Protocol (Rigorous Extrapolation) [cite_start]Human Equivalent Dose (HED): The murine dose utilized in both paradigms was 15 mg/kg[cite: 144]
Its used for type 2 diabetes and has a recently approved cardiovascular label extension, and one oral semaglutide product in development for obesity and cardiovascular risk reduction
Frequently Asked Questions What is the single most important of all GHK-Cu contraindications
Merkler, D., Ernsting, T., Kerschensteiner, M., Brck, W